medigraphic.com
Colegio de Medicina Interna de México.

2014, Number 1

<< Back Next >>

Med Int Mex 2014; 30 (1)

Prothrombin Complex Concentrates at the Emergency Service

Moreno-Carrillo A, Pulido-Arenas J, Bejarano-Zuleta A

Language: Spanish
References: 50
Page: 56-63
PDF size: 480.29 Kb.


ABSTRACT

The prothrombin complex concentrates (PCC) are compounds derived from plasma that incorporates clotting factors dependent on vitamin K. They were developed in 1950 as a source of factor IX for the treatment of hemophilia B and currently their main indication is the reversal of the effects from oral anticoagulants vitamin K antagonists type in emergency situations. Other indications outlined for the use of PCC are the following: replacement therapy for factors II and X in some congenital and acquired defects, coagulopathy associated with severe liver disease, management of perioperative bleeding complications, massive trauma in anticoagulated patients and coagulopathies by sepsis.


REFERENCES

  1. Samama CM. Prothrombin complex concentrates: A brief review. Eur J Anaesthesiol 2008;25:784-789.

  2. Roberts HR, Eberst ME. Current management of hemophilia B. Hematol Oncol Clin North Am 1993;7:1269-1280.

  3. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007;21:37-48.

  4. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007;370:439-448.

  5. Berntorp E, Figueiredo S, Futema L, Pock K, et al. A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors. Blood Coagul Fibrinolysis, 2010;21:577-583.

  6. Baglin TP, Cousins D, Keeling DM, Perry DJ, et al. Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol 2007;136:26-29.

  7. Ansell J, Hirsh J, Hylek E, Jacobson A, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008;133:160-198.

  8. Hellstern P, Halbmayer WM, Kohler M, Seitz R, et al. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res 1999;95:3-6.

  9. Lorenz R, Kienast J, Otto U, Egger K, et al. Efficacy and safety of a prothrombin complex concentrate with two virusinactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003;15:15-20.

  10. Staudinger T, Frass M, Rintelen C, Quehenberger P, et al. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med 1999;25:1105-1110.

  11. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006;4:967-970.

  12. Zareh M, Davis A, Henderson S. Reversal of warfarininduced hemorrhage in the emergency department. West J Emerg Med 2011;12:386-392.

  13. Hanley JP. Warfarin reversal. J Clin Pathol 2004;57:1132- 1139.

  14. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, et al. Clinical review: Prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care 2011;15:201.

  15. Josic D, Hoffer L, Buchacher A, Schwinn H, et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res 2000;100:433-441.

  16. Grobler C, Callum J, McCluskey SA. Reversal of vitamin K antagonists prior to urgent surgery. Can J Anaesth 2010;57:458-467.

  17. Díaz Q. Estudio de coste-efectividad del empleo de concentrado de complejo protrombínico en urgencias para evitar las complicaciones de la sobredosificación de anticoagulantes. Rev Esp Med Urg y Emer 2012;24:113-120.

  18. Palareti G, Leali N, Coccheri S, Poggi M, et al. Bleeding complications of oral anticoagulant treatment: an inceptioncohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-428.

  19. Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis 2010;29:171-181.

  20. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999;14:303-312.

  21. Kagansky N, Knobler H, Rimon E, Ozer Z, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004;164:2044-2050.

  22. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis. Cerebrovasc Dis 1999;9:215- 217.

  23. Glasheen JJ, Fugit RV, Prochazka AV. The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med 2005;20:653-656.

  24. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004;24:1311- 1316.

  25. Fihn SD, Callahan CM, Martin DC, McDonell MB, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996;124:970-979.

  26. Hylek EM, Regan S, Go AS, Hughes RA, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001;135:393-400.

  27. Ansell J, Hirsh J, Poller L, Bussey H, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204-233.

  28. Majeed A, Eelde A, Agren A, Schulman S, et al. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res 2012;129:146-151.

  29. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999;45:1113-1118.

  30. Vigue B, Ract C, Tremey B, Engrand N, et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007;33:721- 725.

  31. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992;23:972-977.

  32. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000;14:458-461.

  33. Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006;67:1272-1274.

  34. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011;124:1573-1579.

  35. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012;10:1841-1848.

  36. Aguilar MI, Hart RG, Kase CS, Freeman WD, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007;82:82-92.

  37. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 2001;115:998-1001.

  38. Ageno W, García D, Aguilar MI, Douketis J, et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol 2009;84:584-588.

  39. Makris M, Watson HG. The management of coumarininduced over-anticoagulation annotation. Br J Haematol 2001;114:271-280.

  40. Pabinger I, Brenner B, Kalina U, Knaub S, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008;6:622-631.

  41. Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol 2002;89:400-406.

  42. Kohler M, Hellstern P, Lechler E, Uberfuhr P, et al. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 1998;80:399-402.

  43. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008;83:137-143.

  44. Bagot CN, Cregg R, Patel RK, Shariff A, et al. Perioperative myocardial infarction in a patient receiving low-dose prothrombin complex concentrates. Thromb Haemost 2007;98:1141-1142.

  45. Riess HB, Meier-Hellmann A, Motsch J, Elias M, et al. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007;121:9-16.

  46. Song MM, Warne CP, Crowther MA. Prothrombin complex concentrate (PCC, Octaplex(R)) in patients requiring immediate reversal of vitamin K antagonist anticoagulation. Thromb Res 2012;129:526-529.

  47. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care 2008;12:105.

  48. Sørensen B, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. Crit Care 2011;15:201.

  49. Lubetsky A, Hoffman R, Zimlichman R, Eldor A, et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004;113:371-378.

  50. Keeling D, Baglin T, Tait C, Watson H, et al. Guidelines on oral anticoagulation with warfarin-fourth edition. Br J Haematol 2011;154:311-324.




2020     |     www.medigraphic.com